Log in to search using one of your social media accounts:

 

Impact of Health Care Insurance Status on Treatment Outcomes of Acute Myeloid Leukemia
Insurance status has been found to influence treatment outcomes in various solid tumors, but limited data is available for patients with acute myeloid leukemia (AML). A total of 161 patients were included in this retrospective study to examine the impact of insurance source in AML outcomes in the state of Oklahoma. Insurance source at diagnosis was found to have no impact on AML treatment outcomes and receipt of bone marrow transplant. The consistency of our results with some, but not all, studies is probably driven primarily by access-to-care requirements among different states. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - May 10, 2017 Category: Hematology Authors: Samer A. Srour, Michael Machiorlatti, Namali T. Pierson, Usman Z. Bhutta, Mohamad Cherry, George B. Selby, David M. Thompson, Sara K. Vesely, Carla D. Kurkjian Tags: Original Study Source Type: research

ZOH é: A Prospective Study of the Use of Biosimilar Filgrastim Zarzio in Clinical Practice in Patients Treated With Chemotherapy for Lymphoid Malignancies
The ZOH é study showed that Zarzio is readily used for prophylaxis of chemotherapy-induced neutropenia in France, and clinicians' assessment of febrile neutropenia risk is driven by patient factors more than the EORTC risk category of the chemotherapy regimen. Maintenance of dose intensity was high, especi ally in patients with non-Hodgkin lymphoma at high risk of neutropenia. Zarzio safety profile was confirmed. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - May 10, 2017 Category: Hematology Authors: Gandhi Laurent Damaj, Omar Benbrahim, Maya Hacini, Inna Voronina, Khaled Benabed, Ravaka-Fatoma Soumoudronga, Isabelle Gasnereau, Corinne Haioun, Philippe Solal-C éligny Tags: Original Study Source Type: research

Viral-induced hemorrhagic cystitis after allogeneic hematopoietic stem cell transplant
Hemorrhagic cystitis (HC) is a well-recognized problem that is regularly observed after hematopoietic stem cell transplantation (HSCT). The published data does not report on the potential risk factors for the viral-induced HC that might require prophylactic treatments. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - May 10, 2017 Category: Hematology Authors: Gilles Dosin, Fouad Aoun, Elie El Rassy, Tarek Assi, Philippe Lewalle, Jeremy Blanc, Roland van Velthoven, Dominique Bron Source Type: research

Expression of peripheral blood miRNA-720 and miRNA-1246 can be used as a predictor for outcome in multiple myeloma patients.
Multiple myeloma(MM) is a heterogeneous disorder, encompassing several related entities that share the common characteristic of being composed of monoclonal plasma cells (PCs). MicroRNAs (miRNAs) are small non-coding RNAs that control the expression of many target messenger RNAs involved in normal cell functions. Two serum microRNAs, miRNA-720 and miRNA-1246, were found to have potential as diagnostic biomarkers in myeloma. Therefore, we investigated a possible correlation of peripheral blood(PB) miRNAs expression with diagnosis, and prognosis. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - May 10, 2017 Category: Hematology Authors: Yuyue Ren, Xiaoyun Li, Wei Wang, Wanting He, Jinghua Wang, Ying Wang Source Type: research

“Outcome and Clinical Significance of Immunophenotypic Markers Expressed in different treatment protocols of T-ALL Pediatric Patients in developing countries
This study aimed to evaluate pediatric patients had T-ALL at two different Arabic cancer centers regarding their clinic-pathologic, immunophenotypic and cytogenetic features and outcome. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - May 10, 2017 Category: Hematology Authors: Douaa M. Sayed, Heba Abdel Razik Sayed, Heba N. Raslan, Amany M. Ali, Asmaa Zahran, Reema Al-Hayek, Saad A. Daama, Arwa Al-Saber Source Type: research

A Multicenter, Open-Label, Phase 1b Study of Carfilzomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients (CHAMPION-2)
The CHAMPION-2 study evaluated 3 dose levels of carfilzomib when given with fixed dose oral cyclophosphamide and dexamethasone for newly diagnosed multiple myeloma. Carfilzomib with cyclophosphamide and dexamethasone is effective and has manageable toxicity. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - May 10, 2017 Category: Hematology Authors: Ralph V. Boccia, Alberto Bessudo, Richy Agajanian, Paul Conkling, Wael Harb, Hui Yang, Dawn Pinchasik, Amy S. Kimball, James R. Berenson Source Type: research

Final results of a phase I study of vorinostat, pegylated liposomal doxorubicin and bortezomib in relapsed or refractory multiple myeloma
Deacetylase inhibitors have synergistic activity in combination with proteasome inhibitors and anthracyclines in preclinical models of multiple myeloma. We therefore evaluated the safety and efficacy of the deacetylase inhibitor vorinostat in combination with pegylated liposomal doxorubicin (PLD) and bortezomib in relapsed/refractory multiple myeloma. Thirty-two patients were treated with PLD and bortezomib in combination with escalating doses of vorinostat on days 4 – 11 or 1 – 14. The maximum tolerated dose of vorinostat was 400 mg on days 4 – 11. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - May 10, 2017 Category: Hematology Authors: Peter M. Voorhees, Cristina Gasparetto, Dominic T. Moore, Diane Winans, Robert Z. Orlowski, David D. Hurd Source Type: research

Impact of Healthcare Insurance Status on Treatment Outcomes of Acute Myeloid Leukemia
We examined the impact of health insurance at diagnosis on AML treatment outcomes. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - May 10, 2017 Category: Hematology Authors: Samer A. Srour, Michael Machiorlatti, Namali T. Pierson, Usman Z. Bhutta, Mohamad Cherry, George B. Selby, David M. Thompson, Sara K. Veseley, Carla D. Kurkjian Source Type: research

Generic Imatinib in Chronic Myeloid Leukemia: Survival of the cheapest
The results of a retrospective analysis, of data from a large group patients with chronic myeloid leukemia (CML) treated with frontline Imatinib mesylate (Innovator/Generic) at a single institution between 2008 and 2014 showed comparable efficacy and safety. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - May 10, 2017 Category: Hematology Authors: Madhav Danthala, Sadashivudu Gundeti, Siva Prasad Kuruva, Krishna Chaitanya Puligundla, Praveen Adusumilli, Ashok Pillai Karnam, Stalin Bala, Meher Lakshmi Konatam, Lakshmi Srinivas Maddali, Raghunadha Rao Digumarti Source Type: research

ZOH é: A prospective study of the use of biosimilar filgrastim Zarzio® in clinical practice in patients treated with chemotherapy for lymphoid malignancies
The ZOH é study showed that Zarzio® is readily used for prophylaxis of chemotherapy-induced neutropenia in France, and clinicians’ assessment of febrile neutropenia risk is driven by patient factors more than the EORTC risk category of the chemotherapy regimen. Maintenance of dose intensity was high, es pecially in non-Hodgkin lymphoma patients at high risk of neutropenia. Zarzio® safety profile was confirmed. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - May 10, 2017 Category: Hematology Authors: Gandhi Laurent Damaj, Omar Benbrahim, Maya Hacini, Inna Voronina, Khaled Benabed, Ravaka-Fatoma Soumoudronga, Isabelle Gasnereau, Corinne Haioun, Philippe Solal-C éligny Source Type: research

Metabolic Syndrome in Long-Term Survivors of Hematopoietic Stem-Cell Transplantation
Since its introduction more than 50 years ago, hematopoietic stem-cell transplantation (HSCT) has transformed from an inescapably fatal procedure to one where cure from malignant and other nonmalignant hematologic diseases is becoming increasingly common. Nevertheless, longevity is not entirely restored. New causes of mortality have emerged; of particular importance is that of increased cardiovascular disease (CVD), related to metabolic syndrome and its components. Controversy exists over whether the metabolic abnormalities induced are a direct effect of HSCT itself or a consequence of other therapies involved. (Source: Cl...
Source: Clinical Lymphoma, Myeloma and Leukemia - May 9, 2017 Category: Hematology Authors: Sophie C. Ragbourne, Martin A. Crook Tags: Review Source Type: research

New Agents in Multiple Myeloma: An  Examination of Safety Profiles
Numerous treatments are available for relapsed and/or refractory multiple myeloma (MM), with safety profiles varying across drug classes and across agents within the same class. Thus, it is important to understand the toxicities of each antimyeloma agent when making treatment decisions. Neutropenia is commonly associated with lenalidomide and pomalidomide, and may be common with histone deacetylase (HDAC) inhibitors, but is relatively unusual with thalidomide, bortezomib, and carfilzomib. Infection was common in trials of lenalidomide and pomalidomide, and upper respiratory tract infection and pneumonia have been seen with...
Source: Clinical Lymphoma, Myeloma and Leukemia - May 9, 2017 Category: Hematology Authors: Sara Bringhen, Edwin De Wit, Meletios-Athanassios Dimopoulos Tags: Review Source Type: research

New Agents in Multiple Myeloma: An Examination of Safety Profiles
Numerous treatments are available for relapsed and/or refractory multiple myeloma (MM), with safety profiles varying across drug classes and across agents within the same class. Thus, it is important to understand the toxicities of each antimyeloma agent when making treatment decisions. Neutropenia is commonly associated with lenalidomide and pomalidomide, and may be common with histone deacetylase (HDAC) inhibitors, but is relatively unusual with thalidomide, bortezomib and carfilzomib. Infection was common in trials of lenalidomide and pomalidomide, and upper respiratory tract infection and pneumonia have been seen with ...
Source: Clinical Lymphoma, Myeloma and Leukemia - May 9, 2017 Category: Hematology Authors: Sara Bringhen, Edwin De Wit, Meletios-Athanassios Dimopoulos Tags: Review Article Source Type: research

Treatment of Peripheral T-Cell Lymphoma in Community Settings
Peripheral T-cell lymphomas (PTCLs) represent a rare and heterogeneous group of malignancies which do not have consensus treatment recommendations. This retrospective review of 93 patients treated in community settings demonstrated considerable variability in treatment strategies. First-line CHOP and CHOP-like regimens were used in 74% of patients, providing 4-year overall survival outcomes of 34% in patients without transplant consolidation and 77% with transplantation. . (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - May 9, 2017 Category: Hematology Authors: Tatyana Feldman, Charles M. Farber, Kelly Choi, Claudio Faria, Andre Goy, Jacqueline Connors, Dhakshila Paramanathan, Sukhi Kaur, Eric Schultz, Michael McGuire, Stuart L. Goldberg Source Type: research

The Metabolic Syndrome in long-term survivors of Haematopoietic Stem Cell Transplantation
Since its introduction more than fifty years ago, haematopoietic stem cell transplantation (HSCT) has transformed from an inescapably fatal procedure to one where cure from malignant and other non-malignant haematological diseases is becoming increasingly common. Nevertheless, longevity is not entirely restored. New causes of mortality have emerged; of particular importance is that of increased cardiovascular disease (CVD), related to metabolic syndrome (MS) and its components. Controversy exists over whether the metabolic abnormalities induced are a direct effect of HSCT itself or a consequence of other therapies involved...
Source: Clinical Lymphoma, Myeloma and Leukemia - May 9, 2017 Category: Hematology Authors: S.C. Ragbourne, M.A. Crook Tags: Review Article Source Type: research

Chronic lymphocytic leukemia patients with deletion 11q have a short time to requirement of first-line therapy, but long overall survival: results of a population-based cohort in British Columbia, Canada
This study documents the clinical course of 67 with high-risk CLL patients with 11q- deletion, from a Provincial CLL database. Aklylator-containing chemotherapies are thought to required to overcome the adverse prognosis associated with 11q-. However, most 11q- patients did not receive alkylators first line and had a median survival of 14.7 years, comparable to the rest of the cohort. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - May 8, 2017 Category: Hematology Authors: Jennifer Goy, Tanya L. Gillan, Helene Bruyere, Steven J.T. Huang, Monica Hrynchak, Aly Karsan, Khaled Ramadan, Joseph Connors, Cynthia L. Toze, Alina S. Gerrie Tags: Original Study Source Type: research

Editorial Board
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - April 29, 2017 Category: Hematology Source Type: research

Table of Contents
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - April 29, 2017 Category: Hematology Source Type: research

Editorial Board
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - April 1, 2017 Category: Hematology Source Type: research

Table of Contents
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - April 1, 2017 Category: Hematology Source Type: research

Can the use of bone marrow parameters improve the efficacy of risk prediction scores in chronic myeloid leukemia in imatinib era??
Development of various risk scores for chronic myeloid leukemia prognostication and intensification of treatment accordingly has been an area of research. Our data confirms that by using bone marrow parameters instead of conventional peripheral blood parameters we could improve efficacy of Sokal and EUTOS risk scores. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - March 29, 2017 Category: Hematology Authors: Govind Babu Kanakasetty, Aditi Harsh Thanky, Lakshmaiah Kuntegowdanahalli, Lokanatha Dasappa, Linu Jacob, Suresh Babu Mallekavu, Rajeev Lakkavalli, Lokesh Kadabur, Rudresha Antapura Tags: Original Study Source Type: research

Elderly Patients with Chronic Myeloid Leukemia Benefit from a Dasatinib dose as Low as 20 mg
A retrospective study of elderly chronic myeloid leukemia (CML) patients aged ≥ 65 years was conducted to evaluate the efficacy and safety of low-dose dasatinib treatment. Reducing the dose of dasatinib below 100 mg/day (even to ≤ 20 mg/day) generated good responses in these patients. The doses were safe and induced rapid and deep molecular responses. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - March 17, 2017 Category: Hematology Authors: Hidekazu Itamura, Yasushi Kubota, Takero Shindo, Toshihiko Ando, Kensuke Kojima, Shinya Kimura Tags: Original Study Source Type: research

Multiple Myeloma: Clinical Updates from the American Society of Hematology Annual Meeting 2016
The benefit from early therapeutic intervention in patients with high-risk smoldering multiple myeloma (SMM) is always a matter of great importance for the myeloma community. In a phase 2 study, 39 patients with high-risk SMM (median age 62 years) were given weekly elotuzumab (10 mg/kg) on days 1, 8, 15, and 22 for the first two 28-day cycles, in combination with lenalidomide on days 1-21 and dexamethasone 40 mg on days 1, 8 and 15 (Arm A). An initial cohort of patients were randomized to receive lower dose of dexamethasone along with elotuzumab and lenalidomide (Arm B) based on the following stratification factors: age>...
Source: Clinical Lymphoma, Myeloma and Leukemia - March 17, 2017 Category: Hematology Authors: Evangelos Terpos, International Myeloma Society Tags: Review Article Source Type: research

Clinical and Serologic Responses After a Two-dose Series of High-dose Influenza Vaccine in Plasma Cell Disorders: A Prospective, Single-arm Trial
The goal of the present study was to evaluate a novel prospective influenza vaccination strategy for patients with plasma cell disorders. Fifty-one patients were treated with a 2-dose series of high-dose inactivated trivalent influenza vaccine. This vaccination strategy was well tolerated and led to very high rates of seroprotection against influenza. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - March 7, 2017 Category: Hematology Authors: Andrew R. Branagan, Eamon Duffy, Randy A. Albrecht, Dennis L. Cooper, Stuart Seropian, Terri L. Parker, Geliang Gan, Fangyong Li, Daniel Zelterman, Chandra Sekhar Boddupalli, Lin Zhang, Rakesh Verma, Thomas M. Ferencz, Madhav V. Dhodapkar Tags: Original Study Source Type: research

Myeloid Sarcoma: Presentation, Diagnosis, and Treatment
Myeloid sarcoma is an extramedullary tumor of immature granulocytic cells. It is a rare condition, most often associated with acute myeloid leukemia (AML), although in some rare cases it may present in nonleukemic patients. It should therefore be considered as a differential diagnosis of any atypical cellular infiltrate. It may occur at any site, leading to very varied clinical presentations. Diagnosis is challenging and relies on a high index of suspicion as well as radiology, histology, immunophenotyping, and molecular analyses, which also are essential for risk stratification and treatment planning. (Source: Clinical Ly...
Source: Clinical Lymphoma, Myeloma and Leukemia - March 7, 2017 Category: Hematology Authors: L. Max Almond, Maria Charalampakis, Samuel J. Ford, David Gourevitch, Anant Desai Tags: Review Source Type: research

Myeloid Sarcoma: Presentation, Diagnosis and Treatment
Myeloid sarcoma is an extramedullary tumour of immature granulytic cells. It is a rare condition, most often associated with acute myeloid leukaemia although in some rare cases it may present in non-leukaemic patients. It should therefore be considered as a differential diagnosis of any atypical cellular infiltrate. It may occur at any site leading to very varied clinical presentations. Diagnosis is challenging and relies on a high index of suspicion as well as radiology, histology, immunophenotyping and molecular analyses, which are also essential for risk stratification and treatment planning. (Source: Clinical Lymphoma,...
Source: Clinical Lymphoma, Myeloma and Leukemia - March 6, 2017 Category: Hematology Authors: L. Max Almond, Maria Charalampakis, Samuel Ford, David Gourevitch, Anant Desai Tags: Review Article Source Type: research

Waldenstr öm Macroglobulinemia: Review of Pathogenesis and Management
Waldenstr öm macroglobulinemia (WM) is a low-grade B-cell clonal disorder characterized by lymphoplasmacytic bone marrow involvement associated with monoclonal immunoglobulin M (IgM). Although WM remains to be an incurable disease with a heterogeneous clinical course, the recent discovery of mutations in the MYD88 and CXCR4 genes further enhanced our understanding of its pathogenesis. Development of new therapies including monoclonal antibodies, proteasome inhibitors, and Bruton’s tyrosine kinase inhibitors have made the management of WM increasingly complex. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - March 6, 2017 Category: Hematology Authors: Seongseok Yun, Ariel Johnson, Onyemaechi Okolo, Stacy J. Arnold, Ali McBride, Ling Zhang, Rachid C. Baz, Faiz Anwer Tags: Review Article Source Type: research

Efficacy and safety of bendamustine and ibrutinib in previously untreated patients with Chronic Lymphocytic Leukemia – indirect comparison
Chronic Lymphocytic Leukemia (CLL) is the most common type of leukemia in adults. Optimal approach to the therapy depends of biology of the disease and of the fitness of patients. In young, fit patients therapeutic goal is to achieve complete remission and even negative minimal residual disease. In elderly, frail patients therapy is directed towards palliation. Recently several new drugs have been introduced in the therapy of CLL. Bendamustine is cytotoxic drug with alkylating and purine analogues features, which is widely used in the therapy of indolent lymphomas including CLL. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - March 6, 2017 Category: Hematology Authors: Iga Andrasiak, Justyna Rybka, Wanda Knopinska-Posluszny, Tomasz Wrobel Tags: Review Article Source Type: research

Clinical and serologic responses following a two dose series of high-dose influenza vaccine in plasma cell disorders: a prospective, single-arm trial
The goal of the present study was to evaluate a novel prospective influenza vaccination strategy in patients with plasma cell disorders. Fifty-one patients were treated with a two dose series of high-dose inactivated trivalent influenza vaccine. This vaccination strategy was well tolerated led to very high rates of seroprotection against influenza. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - March 6, 2017 Category: Hematology Authors: Andrew R. Branagan, Eamon Duffy, Randy A. Albrecht, Dennis L. Cooper, Stuart Seropian, Terri L. Parker, Geliang Gan, Fangyong Li, Daniel Zelterman, Chandra Sekhar Boddupalli, Lin Zhang, Rakesh Verma, Thomas M. Ferencz, Madhav V. Dhodapkar Tags: Original Study Source Type: research

Treating Multiple Myeloma Patients with Oral Therapies
Recent advances have highlighted the importance of long-term, continuous treatment in multiple myeloma (MM) to improve survival. However, treatment burden continues to negatively impact the real-world duration of MM therapy, and strategies to limit the adverse impact of treatment on patient quality of life are therefore particularly important.Oral MM therapies include the immunomodulatory drugs lenalidomide, thalidomide and pomalidomide, the alkylating agents melphalan and cyclophosphamide, the histone deacetylase inhibitor panobinostat, the corticosteroids prednisone and dexamethasone, and the proteasome inhibitor ixazomi...
Source: Clinical Lymphoma, Myeloma and Leukemia - March 6, 2017 Category: Hematology Authors: Shaji Kumar, Ravi Vij, Stephen J. Noga, Deborah Berg, Lonnie Brent, Lawrence Dollar, Ajai Chari Tags: Review Article Source Type: research

Editorial Board
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - February 28, 2017 Category: Hematology Source Type: research

Table of Contents
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - February 28, 2017 Category: Hematology Source Type: research

Prognostic Effect of Complex Karyotype, Monosomal Karyotype, and Chromosome 17  Abnormalities in B-Cell Acute Lymphoblastic Leukemia
The effect of monosomal karyotype (MK), complex karyotype (CK) and chromosome 17 abnormalities on prognosis in B-cell acute lymphoid leukemia (B-ALL) has not yet been established. We conducted a retrospective analysis of prognostic factors on 237 adult patients with B-ALL treated at our institution. Our results showed that MK and CK do not play a predictive role in patients with B-ALL, but further study is required to determine whether specific changes on chromosome 17 might have prognostic value. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - February 16, 2017 Category: Hematology Authors: Priya Khoral, Eshetu G. Atenafu, Kenneth J. Craddock, Aaron Schimmer, Hong Chang Tags: Original Study Source Type: research

Systemic Anaplastic Lymphoma Kinase-positive Anaplastic Large Cell Lymphoma: A Population-based Analysis of Incidence and Survival
We used the Surveillance, Epidemiology, and End Results database to study the incidence and survival of anaplastic lymphoma kinase-positive anaplastic large cell lymphoma. We found that the disease incidence varied significantly by age, gender, and race, whereas survival was influenced by age, race, stage, period of diagnosis, and radiotherapy. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - February 16, 2017 Category: Hematology Authors: Guru Subramanian Guru Murthy, Mehdi Hamadani, Vijaya Raj Bhatt, Ishwori Dhakal, Paulette Mehta Tags: Original Study Source Type: research

The Dana Farber Consortium Protocol for the Treatment of Adolescents and Young Adults With Acute Lymphoblastic Leukemia: A Single Institution Experience in Saudi Arabia
In this retrospective study we sought to evaluate the feasibility of using the Dana Farber Consortium Protocol in Saudi adolescents and young adult patients with acute lymphoblastic leukemia. The 3-year leukemia-free survival and overall survival rates were 70.2% and 72.5%, respectively. Toxicities included infection, mortality during induction, and pancreatitis, but the incidence and severity of osteonecrosis were less than in Western populations, and no venous thromboembolism was found with the use of enoxaparin prophylaxis. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - February 16, 2017 Category: Hematology Authors: Amal S. Alabdulwahab, Hussein G. Elsayed, Mohamed A. Sherisher, Wafa M. Elbjeirami, Nelly Alieldin Tags: Original Study Source Type: research

Clinical Features and Prognosis Analysis of Hodgkin Lymphoma: A Multicenter Retrospective Study Over a Decade of Patients in China
One hundred and fifty patients with newly diagnosed Hodgkin's lymphoma at 4 medical centers over a decade were reviewed. General clinical features were comparable to western patients, while therapeutic outcomes were slightly inferior. A new risk model incorporating traditional risk factors and interim imaging response stratified patients into three classes with distinct outcomes, which warrants further validations for better risk-adapted therapeutic strategy. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - February 15, 2017 Category: Hematology Authors: Wen-Yan Yu, Mei Geng, Jie Hao, Mei Chen, Su-Jiang Zhang, Jin Wang, Jian-Qing Mi Tags: Original Study Source Type: research

Prolonged Use of Zoledronic Acid (4 Years) Did Not Improve Outcome in Multiple Myeloma Patients
To assess whether prolonged use of zoledronic acid (ZA; 4 years) improves outcome in multiple myeloma patients, we performed a clinical trial to compare the effect of 48 and 24 months of treatment. A total of 170 patients were randomly assigned to the 2 groups in the trial. Overall survival was not improved, however, the ZA group showed a reduced number of skeletal events. Thus, we suggest that ZA should be considered to be used for longer duration, in an attempt to improve patient quality of life. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - February 15, 2017 Category: Hematology Authors: Agustin Avil ès, Maria-Jesùs Nambo, Judith Huerta-Guzmàn, Sergio Cleto, Natividad Neri Tags: Original Study Source Type: research

Thoracic Complications in Chronic Lymphocytic  Leukemia
Chronic lymphocytic leukemia (CLL) is the most common adult leukemia. Patients with CLL often present with pulmonary symptoms and diagnoses. We performed a retrospective, single-center chart review evaluating all patients with CLL admitted with a thoracic symptom or diagnosis. Although pneumonia is frequent, there are an increasing number of noninfectious complications, which often require lower respiratory tract sampling. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - February 15, 2017 Category: Hematology Authors: Sameer Khanijo, Pragati Tandon, Cristina P. Sison, Seth Koenig Tags: Original Study Source Type: research

The Efficacy of Generic Imatinib as First- and Second-line Therapy: 3-Year Follow-up of Patients With Chronic Myeloid Leukemia
We examined the long-term clinical outcomes of patients with chronic myeloid leukemia (n  = 41) receiving generic imatinib as first-line (n = 27) and second-line therapy (n = 14) in Bosnia and Herzegovina. Overall survival rates for first-line and second-line generic imatinib were 85% and 100%, respectively. For first-line generic imatinib, complete cytogenetic response was 81%. Gene ric imatinib as second-line therapy does not have deleterious effects on patient outcomes. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - February 15, 2017 Category: Hematology Authors: Erna Islamagic, Azra Hasic, Sabira Kurtovic, Emina Suljovic Hadzimesic, Lejla Mehinovic, Mirza Kozaric, Amina Kurtovic-Kozaric Tags: Original Study Source Type: research

Prognostic Effect of Complex Karyotype, Monosomal Karyotype, and Chromosome 17 abnormalities in B-Cell Acute Lymphoid Leukemia
The impact of monosomal karyotype (MK), complex karyotype (CK) and chromosome 17 abnormalities (abnl 17) on prognosis in B-cell acute lymphoid leukemia (B-ALL) has not yet been established. We conducted a retrospective analysis of prognostic factors on 237 adult patients with B-ALL treated at our institution. Older age (>60), higher white blood cell count (>30), and abnl 17 were associated with shorter overall survival on univariate analysis, but multivariable analysis only identified older age as an independent poor prognostic actor. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - February 15, 2017 Category: Hematology Authors: Priya Khoral, Eshetu G. Atenafu, Kenneth J. Craddock, Aaron Schimmer, Hong Chang Tags: Original Study Source Type: research

The Dana Farber Consortium Protocol (DFCP) for the treatment of adolescents and young adults with acute lymphoblastic leukemia: a single institution experience in Saudi Arabia
This retrospective study sought to evaluate the feasibility of using the Dana Farber Consortium Protocol (DFCP) in Saudi adolescents and young adult patients (AYA) with acute lymphoblastic leukemia (ALL). The 3-year leukemia-free survival (LFS) and overall survival (OS) rates were 68% and 70%, respectively. Toxicities included infection, mortality during induction, and pancreatitis, but the incidence and severity of osteonecrosis were less than in Western populations, and no venous thromboembolism (VTE) was found with the use of enoxaparin prophylaxis. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - February 15, 2017 Category: Hematology Authors: Amal S. Alabdulwahab, Hussein G. Elsayed, Mohamed Atia Sherisher, Wafa M. Elbjeirami, Nelly Alieldin Tags: Original Study Source Type: research

Prolonged Use of Zoledronic ACID ( 4 years) Did Not Improve Outcome In Multiple Myeloma Patients
To assess were prolonged use of zoledronic acid (ZA:4 years) improves outcome in multiple myeloma (MM)patients, we performed a clinical trial, for compared the effect of 48 and 24 months.A total of 170 patients were randomly assigned, to the two groups in the trial.The overall survival was not improved. However ,ZA retain to reduce the number of skeletal events. Thus, we suggested that ZA , will be considered to be employed for longer duration, in attempt to improve patients quality of life. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - February 15, 2017 Category: Hematology Authors: Agustin Avil ès, Maria-Jesùs Nambo, Judith Huerta-Guzmàn, Sergio Cleto, Natividad Neri Tags: Original Study Source Type: research

Thoracic Complications in Chronic Lymphocytic Leukemia (Thoracic Diseases in CLL)
Chronic Lymphocytic Leukemia (CLL) is the most common adult leukemia. Patients with CLL often present with pulmonary symptoms and diagnoses. We performed a retrospective, single center, chart review evaluating all patients with CLL admitted with a thoracic symptom or diagnosis. Although pneumonia is frequent, there are an increasing number of non-infectious complications, which often require lower respiratory tract sampling. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - February 15, 2017 Category: Hematology Authors: Sameer Khanijo, Pragati Tandon, Cristina P. Sison, Seth Koenig Tags: Original Study Source Type: research

Clinical features and prognosis analysis of Hodgkin ’s lymphoma: A multicenter retrospective study over a decade of patients in China
Little information of Hodgkin ’s lymphoma (HL) is available in Chinese patients. We analyzed their clinical features, outcome and prognostic factors aiming to establish a new risk model for better risk-adapted therapeutic strategy. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - February 15, 2017 Category: Hematology Authors: Wen-Yan yu, Mei Geng, Jie Hao, Mei Chen, Su-Jiang Zhang, Jin Wang, Jian-Qing Mi Tags: Original Study Source Type: research

Whole Body MR imaging: A Useful Imaging Modality in the Management of Children with Acute Myeloid Leukemia
Children with acute myeloid leukemia suffer from various complications such as chloromas and disseminated infection or inflammation during their illness. As these complications tend to involve everywhere in the body, whole body MR imaging may be a useful tool in children with acute myeloid leukemia. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - February 15, 2017 Category: Hematology Authors: Hee Mang Yoon, Jeong Rye Kim, Ah Young Jung, Young Ah Cho, Ho Joon Im, Jin Seong Lee Tags: Original Study Source Type: research

Systemic Anaplastic Lymphoma Kinase Positive Anaplastic Large Cell Lymphoma: A Population-based Analysis of Incidence and Survival
We used the SEER database to study the incidence and survival of ALK positive ALCL. We found that the disease incidence varied significantly by age, gender and race, while survival was influenced by age, race, stage, period of diagnosis and radiotherapy. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - February 15, 2017 Category: Hematology Authors: Guru Subramanian Guru Murthy, Mehdi Hamadani, Vijaya Raj Bhatt, Ishwori Dhakal, Paulette Mehta Tags: Original Study Source Type: research

The efficacy of generic imatinib as first- and second-line therapy: three year follow-up of chronic myeloid leukemia patients
We examined the long-term clinical outcomes of CML patients (n=41) receiving generic imatinib as first-line (n=27) and second-line therapy (n=14) in Bosnia and Herzegovina. OS rates for first-line and second-line generic imatinib were 85% vs. 100%, respectively. For first-line generic imatinib, CCyR was 81%. Generic imatinib as second-line therapy does not have deleterious effects on patient outcomes. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - February 15, 2017 Category: Hematology Authors: Erna Islamagic, Azra Hasic, Sabira Kurtovic, Emina Suljovic Hadzimesic, Lejla Mehinovic, Mirza Kozaric, Amina Kurtovic-Kozaric Tags: Original Study Source Type: research

Editorial Board
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - January 31, 2017 Category: Hematology Source Type: research

Table of Contents
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - January 31, 2017 Category: Hematology Source Type: research

The Society of Hematologic Oncology (SOHO): Continuing to Move Forward in the Battle against Hematologic Malignancies
The Society of Hematologic Oncology (SOHO) is an international society designed specifically for clinicians, research scientists and related health care professionals who specialize in the research and treatment of patients with hematologic malignancies. SOHO ’s mission is to promote worldwide research and education through the exchange of scientific information. Organized by its founders and world class committees, SOHO is the only international society specific to this field. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - January 17, 2017 Category: Hematology Authors: Hagop Kantarjian Tags: Editorial Source Type: research